gamma Synuclein (SNCG) Rabbit Polyclonal Antibody
CAT#: AP06417PU-N
gamma Synuclein (SNCG) rabbit polyclonal antibody, Aff - Purified
Need it in bulk or conjugated?
Get a free quote
CNY 4,640.00
货期*
2周
规格
Specifications
Product Data | |
Applications | IHC, WB |
Recommend Dilution | Western blot: 1/500-1/1000. Immunohistochemistry on paraffin sections: 1/50-1/200. |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Immunogen | Synthetic peptide, corresponding to amino acids 81-130 of Human Synoretin. |
Specificity | This antibody detects endogenous levels of Synuclein γ protein. (region surrounding Ala111) |
Formulation | Phosphate buffered saline (PBS), pH 7.2. State: Aff - Purified State: Liquid purified Ig fraction Preservative: 0.05% sodium azide |
Concentration | 1.0 mg/ml |
Purification | Affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) |
Conjugation | Unconjugated |
Storage Condition | Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. |
Predicted Protein Size | ~ 20 kDa |
Gene Name | synuclein gamma |
Database Link | |
Background | The synucleins, including alpha-synuclein (also designated NACP for nonamyloid component precursor), beta-synuclein (also designated PNP 14 for phosphoneuroprotein 14), and gamma-synuclein (also designated persyn or BCSG1 for breast cancer-specific gene 1) are presynaptic proteins abundant in neurons. alpha-Synuclein, identified as a component of Alzheimers disease amyloid plaques, is localized to neuronal cell bodies and synapses. Coordinate expression of alpha-synuclein and beta-synuclein may be important during hematopoetic cell differentiation. A mutant form of alpha-synuclein is found in patients with early onset Parkinsons disease. gamma-Synuclein is associated with axonal pathology in Parkinsons disease. |
Synonyms | PERSYN, Synuclein gamma, Synoretin, BCSG1, PRSN |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...